Repository logo
 

Neurophysiological Progression in Alzheimer's Disease: Insights From Dynamic Causal Modelling of Longitudinal Magnetoencephalography.

Accepted version
Peer-reviewed

Loading...
Thumbnail Image

Change log

Abstract

Neurodegenerative diseases, including Alzheimer's disease, are characterised by selective neuronal vulnerability with regional, laminar, cellular and neurotransmitter specificity. The regional losses of neurons and their synapses are associated with neurophysiological changes and cognitive decline. Hypotheses related to these mechanisms can be tested and compared by dynamic causal modelling (DCM) of human neuroimaging data, including magnetoencephalography (MEG). In this paper, we use DCM of cross-spectral densities to model changes between baseline and follow-up data in cortical regions of the default mode network, to characterise longitudinal changes in cortical microcircuits and their connectivity underlying resting-state MEG. Twenty-nine people with amyloid-positive mild cognitive impairment and Alzheimer's disease early dementia were studied at baseline and after an average interval of 16 months. To study longitudinal changes induced by Alzheimer's disease, we evaluate three complementary sets of DCM: (i) with regional specificity, of the contributions of neurons to measurements to accommodate regional variability in disease burden; (ii) with dual parameterisation of excitatory neurotransmission, motivated by preclinical and clinical evidence of distinct effects of disease on AMPA versus NMDA type glutamate receptors; and (iii) with constraints to test specific clinical hypothesis about the effects of disease-progression. Bayesian model selection at the group level confirmed evidence for regional specificity of the effects of Alzheimer's disease, with evidence for selective changes in NMDA neurotransmission, and progressive changes in connectivity within and between Precuneus and medial prefrontal cortex. Moreover, alterations in effective connectivity vary in accordance with individual differences in cognitive decline during follow-up. These applications of DCM enrich the mechanistic understanding of the pathophysiology of human Alzheimer's disease and inform experimental medicine studies of novel therapies. More generally, longitudinal DCM provides a potential platform for natural history and interventional studies of neurodegenerative and neuropsychiatric diseases, with selective neuronal vulnerability.

Description

Journal Title

Hum Brain Mapp

Conference Name

Journal ISSN

1065-9471
1097-0193

Volume Title

Publisher

Wiley

Rights and licensing

Except where otherwised noted, this item's license is described as Attribution 4.0 International
Sponsorship
Wellcome Trust (220258/Z/20/Z)
MRC (via University of Oxford) (MR/T033371/1)
MRC (MC_UU_00030/14)
National Institute for Health Research (NIHR) (via NHS Cambridgeshire and Peterborough Integrated Care Board (ICB)) (OH-BRC NIHR203316)
This work is primarily funded by the Wellcome Trust (220258) and Dementias Platform UK funded by the Medical Research Council (MC_UU_00030/14 & MR/T033371/1), Janssen, AstraZeneca, Araclon, IXICO, Somalogic, GlaxoSmithKline, Invicro, Cambridge Cognition and Cognetivity. The study has additional support from Alzheimer’s Research UK (ARUK-PG2017B-19), NIHR Cambridge Biomedical Research Centre (NIHR203312) and NIHR Oxford Health Biomedical Research Centre (NIHR203316). The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. For the purpose of open access, the authors have applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission.